Declan Walsh

Declan Walsh

Auto-generated profile, based on publicly available information

Declan Walsh

Levin Cancer, Atrium Health Levine Cancer Institute, Charlotte, North Carolina, USA

Research Focus & Metrics

Academic Career Length

45Years (1982-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2011 in The Lancet Oncology
Verified
Journal Article
Closed access
KFKenneth Fearon
Kenneth Fearon
FSFlorian Strasser
Florian Strasser
SAStefan D Anker
Stefan D Anker
IBIngvar Bosaeus
Ingvar Bosaeus
EBEduardo Bruera
Eduardo Bruera
Vickie Elaine BaracosVickie Elaine Baracos
Vickie Elaine Baracos

13 March 2000 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
DWD. Walsh
D. Walsh
SDS. Donnelly
S. Donnelly
LRL. Rybicki
L. Rybicki

30 December 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
SSShiva Shrotriya
Shiva Shrotriya
DWDeclan Walsh
Declan Walsh
NBNabila Bennani-Baiti
Nabila Bennani-Baiti
STShirley Thomas
Shirley Thomas
CLCliona Lorton
Cliona Lorton
A systematic literature review was done to determine the relationship between elevated CRP and prognosis in people with solid tumors. C-reactive protein (CRP) is a serum acute phase reactant and a well-established inflammatory marker. We also examined the role of CRP to predict treatment response and tumor recurrence. MeSH (Medical Subject Heading) terms were used to search multiple electronic databases (PubMed, EMBASE, Web of Science, SCOPUS, EBM-Cochrane). Two independent reviewers selected research papers. We also included a quality Assessment (QA) score. Reports with QA scores <50% were excluded. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis) methodology was utilized for this review (S1 PRISMA Checklist). 271 articles were identified for final review. There were 45% prospective studies and 52% retrospective. 264 had intermediate QA score (≥50% but <80%); Seven were adequate (80% -100%); A high CRP was predictive of prognosis in 90% (245/271) of studies—80% of the 245 studies by multivariate analysis, 20% by univariate analysis. Many (52%) of the articles were about gastrointestinal malignancies (GI) or kidney malignancies. A high CRP was prognostic in 90% (127 of 141) of the reports in those groups of tumors. CRP was also prognostic in most reports in other solid tumors primary sites. A high CRP was associated with higher mortality in 90% of reports in people with solid tumors primary sites. This was particularly notable in GI malignancies and kidney malignancies. In other solid tumors (lung, pancreas, hepatocellular cancer, and bladder) an elevated CRP also predicted prognosis. In addition there is also evidence to support the use of CRP to help decide treatment response and identify tumor recurrence. Better designed large scale studies should be conducted to examine these issues more comprehensively.

20 March 2006 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
JKJordanka Kirkova
Jordanka Kirkova
MDMellar P. Davis
Mellar P. Davis
DWDeclan Walsh
Declan Walsh
ETEoin Tiernan
Eoin Tiernan
NONorma O'LEary
Norma O'LEary
KRK. Mitchell Russell
K. Mitchell Russell
Purpose A variety of assessment instruments have been created to identify cancer symptoms. We reviewed systematically cancer symptom assessment instruments published in English. Methods A systematic search of the MEDLINE database, Cochrane Library, Cumulative Index of Nursing and Allied Health Literature (CINAHL), and EMBASE was performed. Non–peer-reviewed articles were identified through BIOSIS. Articles were accessed through the related article links in PubMed and references were searched by hand. Studies were included if the instrument had symptom assessment as the primary outcome. Quality-of-life instruments were excluded. Results We identified 21 instruments; some had undergone modification or validation. An additional 28 studies examined symptom prevalence and interrelations; many involved symptom checklists. Studies varied in design, patient characteristics, symptoms, and outcome. Meta-analysis was not possible due to heterogeneity in design, study outcomes, and validation. Seventy-six articles and two conference abstracts (derived from MEDLINE, Cochrane, CINAHL, EMBASE, BIOSIS, related articles link in PubMed, and search by hand) met inclusion/exclusion criteria. The electronic search (without related links) yielded only 26% of those articles and conference abstracts that met inclusion criteria. Searches by hand of related articles identified 59% of studies. Conclusion Twenty-one instruments were identified as appropriate for clinical use. The instruments vary in symptom content and extent of psychometric validation. Both comprehensive and shorter instruments have been developed, and some instruments are intended for specific symptom assessment or symptoms related to treatment. There is no ideal instrument, and the wide variety of instruments reflects the different settings for symptom assessment. Additional research is necessary.

16 February 2006 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
DWDeclan Walsh
Declan Walsh
LRLisa Rybicki
Lisa Rybicki

20 November 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TYTugba Yavuzsen
Tugba Yavuzsen
MDMellar P. Davis
Mellar P. Davis
DWDeclan Walsh
Declan Walsh
SLSusan LeGrand
Susan LeGrand
RLRuth Lagman
Ruth Lagman
Purpose We systematically assessed the efficacy and safety of appetite stimulants in the management of cancer-related anorexia. Literature databases were searched for randomized controlled trials of appetite stimulants in the treatment of cancer anorexia. Materials and Methods Studies were graded according to quality. Fifty-five studies met inclusion criteria. Results Only two drugs have evidence to support their use for anorexia (progestins and corticosteroids). There is strong evidence against the use of hydrazine sulfate. The outcomes of these trials have been mixed and patient population heterogeneous. Conclusion The optimal dose, time to start, and duration of treatment for many appetite stimulants for cancer anorexia is still unknown. A more systematic approach to research methodology with universal outcome measure and prospective randomized studies are needed. Combination regimens are needed but this cannot at the present time be supported by the data presented.